Search

Your search keyword '"Keating, Karen"' showing total 209 results

Search Constraints

Start Over You searched for: Author "Keating, Karen" Remove constraint Author: "Keating, Karen"
209 results on '"Keating, Karen"'

Search Results

3. TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting

4. The role of the estimand framework in the analysis of patient-reported outcomes in single-arm trials: a case study in oncology.

12. Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures

13. Single-arm studies involving patient-reported outcome data in oncology: a literature review on current practice

17. Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers

18. Updated health-related quality of life of patients with TRK-fusion cancer treated with larotrectinib in clinical trials.

21. Abstract 152: A machine learning approach to detect FFPE artefacts leads to accurate estimation of tumor mutational burden from sequencing data without a matched normal

22. Abstract 394: Prognosis and molecular characteristics of patients with TRK fusion cancer in the 100,000 Genomes Project

23. sj-pdf-1-tam-10.1177_1758835920975613 – Supplemental material for A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors

24. Intra-patient comparison from larotrectinib clinical trials in TRK fusion cancer: An expanded dataset.

25. sj-pdf-1-tam-10.1177_1758835920975613 – Supplemental material for A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors

26. Larotrectinib versus prior therapies in tropomyosin receptor kinase fusion cancer:An intra-patient comparative analysis

30. Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis

31. 798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update

33. Quality of life of adults and children with TRK fusion cancer treated with larotrectinib compared to the general population.

34. Growth modulation index (GMI) as a comparative efficacy measure of larotrectinib versus prior systemic treatments for TRK fusion cancer patients.

39. A 'gap' between physician and patient assessment of symptom severity in acute cystitis? A multicenter trial of women treated with extended-release ciprofloxacin

40. Educating patients with uncomplicated UTIs: the effect of an educational brochure on patient knowledge

42. Does recall period matter? Comparing PROMIS® physical function with no recall, 24-hr recall, and 7-day recall

43. Costs associated with follicular lymphoma among individuals diagnosed with non-Hodgkin lymphoma: a longitudinal analysis using SEER-Medicare data

44. Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancer receiving larotrectinib.

45. A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors.

46. Transforming approaches to treating TRK fusion cancer: historical comparison of larotrectinib and histology-specific therapies.

47. Validation of a patient-administered questionnaire to measure the activity impairment experienced by women with uncomplicated urinary tract infection: the Activity Impairment Assessment (AIA)

48. Does recall period matter? Comparing PROMIS® physical function with no recall, 24-hr recall, and 7-day recall.

49. Costs associated with follicular lymphoma among individuals diagnosed with non-Hodgkin lymphoma: a longitudinal analysis using SEER-Medicare data.

Catalog

Books, media, physical & digital resources